Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
IPO Year: 2013
Exchange: NASDAQ
Website: arcturusrx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $32.00 | Sector Outperform | Scotiabank |
| 1/28/2025 | $41.00 | Buy | BTIG Research |
| 8/12/2024 | $70.00 | Outperform | Leerink Partners |
| 12/13/2023 | $90.00 | Buy | Canaccord Genuity |
| 7/24/2023 | $71.00 | Outperform | William Blair |
| 5/11/2023 | $19.00 → $51.00 | Neutral → Buy | H.C. Wainwright |
| 11/14/2022 | $35.00 | Overweight | Wells Fargo |
| 11/10/2022 | $18.00 | Neutral → Underperform | Robert W. Baird |
| 11/3/2022 | $22.00 → $35.00 | Neutral → Buy | Citigroup |
| 11/2/2022 | $16.00 → $25.00 | Underweight → Equal Weight | Barclays |
10-Q - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
10-Q - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
DEF 14A - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)
Fastest customizable press release news feed in the world
Cystic fibrosis (ARCT-032) Phase 2 interim data from first nine participants to be presented in September Cystic fibrosis Phase 2 trial expected to complete enrollment by year end 2025 OTC deficiency (ARCT-810) Phase 3 trial design alignment with regulatory agencies expected H1 2026 Seasonal flu (ARCT-2138) showed positive Phase 1 results BARDA pandemic flu (ARCT-2304) Phase 1 results expected 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, tod
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2025 after the market close on Monday, August 11 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 11, 2025. Arcturus Therapeutics Second Quarter 2025 Earnings Conference Call Monday, August 11, 2025 @ 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS Webcast: Link Abou
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: BTIG Virtual Biotechnology Conference 2025 (Fireside Chat) Tuesday, July 29, 2025 (12:40 p.m. ET) CG 45th Annual Growth Conference (Presentation) Tuesday, August 12, 2025 (8:30 a.m. ET) About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a commercial mRNA medicines and vaccines com
ARCT-810 significantly and consistently reduces biomarker glutamine to levels within normal range 15N-ureagenesis data provide first evidence of an mRNA therapeutic improving urea cycle function Ammonia remained stable and within normal range Multiple administrations of ARCT-810 continue to be safe and well tolerated at all tested dose levels Virtual KOL Presentation at 12:00 p.m. ET Today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announces positive Phase 2 interim results in
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will host a virtual KOL presentation of ARCT-810 Phase 2 interim data for Ornithine Transcarbamylase (OTC) deficiency on Monday, June 30, 2025, at 12:00 p.m. ET. The Company will issue a press release summarizing the data at 11 am ET, prior to the presentation. The KOL presentation will review Arcturus' interim clinical data from ARCT-810 Phase 2 trials evaluating the safety and pharmacodynamics of multiple doses of ARCT-810
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: Jefferies Global Healthcare Conference (Presentation) Wednesday, June 4, 2025 (4:20 p.m. ET) Goldman Sachs Annual Global Healthcare Conference (Fireside Chat) Monday, June 9, 2025 (3:20 p.m. ET) About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a commercial mRNA medicines and vacc
Prioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025 ARCT-032 (CF) Phase 2 expected to complete enrollment by year end ARCT-810 (OTC) Phase 2 interim data expected Q2 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates. "We are delight
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025. Arcturus Therapeutics First Quarter 2025 Earnings Conference Call Monday, May 12, 2025 @ 4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS Webcast: Link About Arcturus Foun
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, designed for active immunization to protect against disease caused by influenza A H5N1 subtype contained in the vaccine. This designation recognizes the potential of ARCT-2304 as an innovative approach to address unmet medical needs for the prevention of disease caused by pandemic influ
Phase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025 Meiji Seika Pharma and ARCALIS received MHLW approval for commercial manufacturing of KOSTAIVE® Meiji Seika Pharma Submitted Application for Two-Dose Vial of KOSTAIVE® KOSTAIVE® U.S. BLA filing anticipated 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updat
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)
Scotiabank initiated coverage of Arcturus Therapeutics with a rating of Sector Outperform and set a new price target of $32.00
BTIG Research initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $41.00
Leerink Partners initiated coverage of Arcturus Therapeutics with a rating of Outperform and set a new price target of $70.00
Canaccord Genuity initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $90.00
William Blair initiated coverage of Arcturus Therapeutics with a rating of Outperform and set a new price target of $71.00
H.C. Wainwright upgraded Arcturus Therapeutics from Neutral to Buy and set a new price target of $51.00 from $19.00 previously
Wells Fargo resumed coverage of Arcturus Therapeutics with a rating of Overweight and set a new price target of $35.00
Robert W. Baird downgraded Arcturus Therapeutics from Neutral to Underperform and set a new price target of $18.00
Citigroup upgraded Arcturus Therapeutics from Neutral to Buy and set a new price target of $35.00 from $22.00 previously
Barclays upgraded Arcturus Therapeutics from Underweight to Equal Weight and set a new price target of $25.00 from $16.00 previously
Live Leadership Updates
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company's Board of Directors since June 2024. "Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate," said Joseph Payne, President & Chief Executive Officer of Arcturus. "We look forward to working with him as we enter a transformative yea
Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors. "Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and comm
Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company's vaccine franchise Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Markels will provide strategic oversight to the C
PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., ("Krystal") (NASDAQ:KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new member of the Board of Directors. Dr. Marantz is an experienced biopharmaceutical industry executive who has held senior level positions in medical affairs, business development, and commercial strategy in multiple therapeutic areas, including rare diseases. Dr. Sutherland is a pulmonologist by training with deep clinical knowledge combined with R&D and corporate strategy leadership across pulmonary and rare diseases. In connection with
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the appointment of Jing Marantz, M.D., Ph.D., M.B.A., an experienced biopharma industry executive, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005321/en/Jing L Marantz, M.D., Ph.D., M.B.A. (Photo: Business Wire) "We are very pleased to welcome Dr. Jing Marantz, to the Arcturus Board," said Joseph Payne, President &
This live feed shows all institutional transactions in real time.
SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)
Live finance-specific insights
Cystic fibrosis (ARCT-032) Phase 2 interim data from first nine participants to be presented in September Cystic fibrosis Phase 2 trial expected to complete enrollment by year end 2025 OTC deficiency (ARCT-810) Phase 3 trial design alignment with regulatory agencies expected H1 2026 Seasonal flu (ARCT-2138) showed positive Phase 1 results BARDA pandemic flu (ARCT-2304) Phase 1 results expected 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, tod
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2025 after the market close on Monday, August 11 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 11, 2025. Arcturus Therapeutics Second Quarter 2025 Earnings Conference Call Monday, August 11, 2025 @ 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS Webcast: Link Abou
Prioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025 ARCT-032 (CF) Phase 2 expected to complete enrollment by year end ARCT-810 (OTC) Phase 2 interim data expected Q2 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates. "We are delight
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025. Arcturus Therapeutics First Quarter 2025 Earnings Conference Call Monday, May 12, 2025 @ 4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS Webcast: Link About Arcturus Foun
Phase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025 Meiji Seika Pharma and ARCALIS received MHLW approval for commercial manufacturing of KOSTAIVE® Meiji Seika Pharma Submitted Application for Two-Dose Vial of KOSTAIVE® KOSTAIVE® U.S. BLA filing anticipated 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updat
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2024 after the market close on Thursday, March 6 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 6, 2025. Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call Thursday, March 6, 2025 @4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURU
Cystic Fibrosis and OTC Deficiency Phase 2 studies on track for POC data in first half of 2025 $25 Million commercial milestone achieved with first sale of KOSTAIVE® in Japan KOSTAIVE® European CHMP opinion expected December Positive results from multiple Phase 3 studies support KOSTAIVE® U.S. BLA filing in H1 2025 Superior 12-month durability results from Phase 3 study of KOSTAIVE® published in The Lancet Infectious Diseases Positive Phase 3 results showed KOSTAIVE® XBB.1.5. met all four primary study objectives and key secondary objectives Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messe
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA vaccines and medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended September 30, 2024 after the market close on Thursday, November 7 and will also host a conference call and webcast at 4:30 pm Eastern Time on November 7, 2024. Arcturus Therapeutics Third Quarter 2024 Earnings Conference Call Thursday, November 7, 2024 @ 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference I
IND submitted for Phase 2 trial of ARCT-032 targeting cystic fibrosis (CF) ARCT-810 (OTC deficiency) Phase 2 interim data on track for Q4 Kostaive® on track for Q4 commercial launch in Japan Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided corporate updates. "We are pleased to remain on track for our first commercial product launch of Ko
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2024 after the market close on Monday, August 5 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 5, 2024. Arcturus Therapeutics Second Quarter 2024 Earnings Conference Call Monday, August 5, 2024 @ 4:30 p.m. ET Domestic: 1-877-407-0784 International: 1-201-689-8560 Conference ID: 13747924 Web